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ABSTRACT
Objective: The objective of this work is to develop a simple, precise, rapid, and low-cost conductometric method for the determination of etilefrine 
hydrochloride, fenoterol hydrobromide, and pipazethate hydrochloride in pure form and in pharmaceutical formulations using silver nitrate.
Methods: The method is based on the precipitation of chloride or bromide ions coming from the cited drugs with silver ions yielding silver chloride 
or silver bromide, and the conductance of the solution is measured as a function of the volume of titrant. The studied drugs were evaluated in double 
distilled water in the range of 1-10 mg; various experimental conditions were established.
Results: Results obtained showed good recoveries with relative standard deviation of 0.684, 0.817, and 0.864 for etilefrine hydrochloride, fenoterol 
hydrobromide, and pipazethate hydrochloride, respectively. The proposed procedures were applied successfully to the analysis of these drugs in their 
pharmaceutical formulations; results were successfully comparable to the official or reference methods.
Conclusion: Simple and rapid procedure described in this work can be an alternative to the more complex and expensive methods for assay of the 
cited drugs.
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INTRODUCTION
Etilefrine hydrochloride [2-Ethylamino-1-(3-hydroxyphenyl) ethanol 
hydrochloride] [1] is a direct-acting sympathomimetic with beta1-
agonist properties, and some alpha- and beta2-agonist actions. It is 
used for the treatment of hypotensive states [2]. Different techniques 
were reported for the determination of etilefrine hydrochloride 
including spectrophotometry [3,4], spectrofluorimetry [5], automated 
sequential injection spectrophotometry [6], Flow-injection 
spectrophotometry [7], flow-injection chemiluminometric assay [8], 
and high-performance liquid chromatography [9].
Fenoterol hydrobromide [(1RS)-1-(3,5-dihydoxyphenyl)-2-[[(1RS)-2-
(4-hydroxyphenyl)-1-methylethyl]amino]ethanol hydrobromide] [1] 
is direct-acting sympathomimetic with beta-adrenoceptor stimulant 
activity largely selective for beta2 receptors (a beta2 agonist). It is 
used as a bronchodilator in the management of reversible airways 
obstruction, as occurs in asthma and in some patients with chronic 
obstructive pulmonary disease [2]. Various analytical methods have 
been applied for the determination of fenoterol hydrobromide in 
raw material, pharmaceuticals, and biological fluids. These methods 
include liquid chromatography [10-12], gas chromatography [13], 
voltammetry [14], electrophoresis [15,16], spectrophotometry [17,18], 
and spectrofluorimetry [19].
Pipazethate HCl (2-(2-piperidinoethoxy) ethyl 10H-pyrido [3,2-b]
[1,4]benzothiadiazine-10-carboxylate hydrochloride is a centrally 
acting cough suppressant which also has some peripheral actions 
in a non-productive cough [2]. Different techniques were reported 
for the determination of pipazethate hydrochloride including 
spectrophotometry [20-24], electrochemical [25-26], and 
chromatographic [27] methods.
Silver nitrate has been used for conductometric determination of 
many drugs such as naftidrofuryl oxalate, propafenone HCl and sotalol 




Conductometer model 470 portable conductivity/TDS meter, 25 DEG. 
C-C10 dip-type cell was used with a cell constant, Kcell, of 1.09.
Materials and reagents
All materials and reagent used were of analytical grade, solvents were 
of spectroscopic grade, and bidistilled water was used.
1. Etilefrine HCl (obtained from chemical industrial development, CID)
2. Fenoterol hydrobromide (obtained from Sigma Pharmaceutical 
Industries)
3. Pipazethate hydrochloride (obtained from Egyptian International 
Pharmaceutical Industries Company [EPICO])
4. (5×10−3 M) Silver nitrate.
Standard drug solutions
Aqueous solutions of 1 mg/ml were prepared by dissolving 100 mg of 
the pure drug of etilefrine hydrochloride, fenoterol hydrobromide, and 
pipazethate hydrochloride in 100 ml bidistilled water.
Pharmaceutical preparations
1. Effortil® tablets containing 5 mg etilefrine HCl per tablet (obtained 
from CID under the licence of Boehringer Ingelheim Germany).
2. Effortil® Drops containing 7.5 mg etilefrine HCl per gm solution (obtained 
from CID under the licence of Boehringer Ingelheim, Germany).
3. Pronotrol® Syrup containing 2.5 mg fenoterol HBr per 5 ml (obtained 
from Sigma Pharmaceutical Industries).
4. Selgon® tablets containing 20 mg pipazethate hydrochloride per 
tablet (obtained from EPICO).
5. Selgon® Drops containing 40 mg pipazethate hydrochloride per ml 
solution (obtained from EPICO).
Research Article
General procedure
Aliquots of drug solution (1-10 ml) containing 1-10 mg pure drug were 
transferred to a 50 ml calibrated flasks; volumes were made up to the mark 
using bidistilled water. The contents of the calibrated flask were transferred 
to a beaker; the conductivity cell was immersed and 5×10−3 M silver nitrate 
was used for titration. The conductance was measured subsequent to each 
addition of reagent solution and after thorough stirring for 2 minutes; the 
conductance was corrected for dilution [32] using the following equation, 




Where Ωcorrect is the corrected electrolytic conductivity, Ωobs is the 
observed electrolytic conductivity, v1 is the initial volume and v2 is the 
volume of reagent added.
A graph of corrected conductivity versus the volume of added titrant 
was constructed, and end-point was determined conductometrically.
The amount of drugs under study was calculated according to the 
following equation:
Amount of drug=VMR/N
Where V is volume of titrant, M is molecular weight of drug, R is molar 
concentration of titrant and N is N0 of moles of titrant consumed by one 
mole of drug.
Assay of the pharmaceutical formulations
Assay tablets
About 10 tablets were powdered and an amount equivalent to 100 mg 
etilefrine hydrochloride and pipazethate hydrochloride was shaken 
with 10 ml distilled water, then diluted to 100 ml with distilled water 
and filtered. The procedure was completed as in general procedure.
Assay of syrup and drops
Specific volumes of syrup and drops solutions equivalent to 100 mg pure 
drug were placed in 100 ml volumetric flask and diluted to 100 ml with 
distilled water for etilefrine hydrochloride, fenoterol hydrobromide, 
and pipazethate hydrochloride. The procedure was completed as in 
general procedure.
RESULTS AND DISCUSSION
The conductometric methods of analysis are well suited for the 
determination of endpoints in precipitation titrations, where the shape of 
the titration curves can be predicted by summing the ionic conductance 
of the various species during the course of titration. On using silver 
nitrate as a titrant for the determination of etilefrine hydrochloride, 
fenoterol hydrobromide, and pipazethate hydrochloride - silver chloride 
or silver bromide is precipitated leading to a straight line during the 
first segment of the titration curve. The second segment of this curve 
corresponds to the excess of AgNO3 (Figs. 1-3).
Investigations were carried out to establish the most favorable 
conditions for the reaction attain end point. The influence of some 
variables on the reaction has been tested as follow:
The optimum conditions for performing the titration in a quantitative 
manner were elucidated as described as follows:
1. Titrations in different media were attempted to obtain the best 
results - Preliminary experiments in:
i. Aqueous solutions of both drug and reagent,
ii. Ethanolic solutions of both drug and reagent,
iii. Drug and reagent solutions in ethanol–water (50%, v/v) mixture,
iv. Methanolic solutions of both drug and reagent,
v. Drug and reagent solutions in methanol-water (50% v/v) mixture,
vi. Acetone solutions of both drug and reagent, and
vii. Drug and reagent solution in acetone–water (50% v/v) mixture.
Preliminary experiments showed that procedure in aqueous media was 
the most suitable for successful results (higher conductance and most 
sharp end point.).
Fig. 1: Conductometric titration curve of 5 mg etilefrine 
hydrochloride versus (5×10−3) M silver nitrate
Fig. 2: Conductometric titration curve of 5 mg fenoterol 
hydrobromide versus (5×10−3) M silver nitrate
Fig. 3: Conductometric titration curve of 5 mg sotalol HCl versus 
(5×10−3) M silver nitrate
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2. Reagent’s concentration
 The optimum concentrations of silver nitrate were 5×10−3 M 
to achieve a constant and highly stable conductance reading 
after 2.0 minutes mixing. Concentrations less than these lead to 
unstable readings and more time was needed to obtain constant 
conductance values.
3. Effect of temperature
 On raising the temperature to 40°C, no change in the conductance 
reading was observed, so the experiment was done at room 
temperature.
Validation of the studied method
To address the validity of the proposed method, a statistical analysis of 
the data obtained from its application on drugs in the pure form and 
in pharmaceutical formulations was performed. Results revealed in 
Tables 1-3 showed that the proposed method is satisfactorily accurate, 
precise, and reproducible over a concentration range of 1-10 mg for all 
of the studied drugs.
Student’s t-test and F-test (at 95% confidence level) were applied to the 
results obtained compared with that obtained when applying the official 
Table 1: Conductometric determination etilefrine hydrochloride, fenoterol hydrobromide, and
 pipazethate hydrochloride using silver nitrate
Etilefrine hydrochloride Fenoterol hydrobromide Pipazethate hydrochloride
Taken (mg) Found (mg) Recovery (%) Taken (mg) Found (mg) Recovery (%) Taken (mg) Found (mg) Recovery (%)
1 1.012 101.23 1 0.999 99.91 1 1.007 100.73
3 2.993 99.78 3 3.017 100.55 2 2.956 98.54
5 5.007 100.14 5 5.072 101.45 5 5.037 100.73
7 7.021 100.29 7 7.013 100.19 7 7.007 100.11
9 8.925 99.17 9 9.030 100.34 9 8.978 99.76
10 10.041 100.41 10 9.895 99.95 10 10.073 100.73
Mean±SD 100.17±0.685 100.23±0.817 100.10±0.865
N 6 6 6
V 0.469 0.668 0.748
SD 0.685 0.817 0.865
RSD 0.684 0.815 0.784
SE 0.242 0.289 0.306
SD: Standard deviation, RSD: Relative standard deviation, SE: Standard error
Table 2: Conductometric determination of etilefrine hydrochloride and fenoterol hydrobromide in their































1 - 1.001 100.14 1 - 0.990 101.37 1 - 0.999 99.91
1 0.990 99.05 1 1.001 100.14 1 0.999 99.91
3 3.026 100.86 3 3.037 101.23 3 3.036 101.19
5 4.985 99.70 5 4.996 99.92 5 4.957 99.14
7 7.053 100.76 7 6.955 99.36 7 7.071 101.01
9 9.012 100.14 9 9.023 100.26 9 8.992 99.91
Mean±SD 100.10±0.755 100.18±0.679 100.32±0.854
N 5 5 5
V 0.570 0.461 0.730
SD 0.755 0.679 0.854
SE 0.267 0.240 0.302
SD: Standard deviation, SE: Standard error
Table 3: Conductometric determination of pipazethate hydrochloride in its pharmaceutical preparations using silver nitrate

















1 - 1.029 102.92 1 - 1.007 100.73
1 1.007 100.73 1 1.007 100.73
3 2.978 99.27 3 3.066 102.19
5 5.102 102.05 5 5.015 100.29
7 7.073 101.05 7 6.986 99.79






SD: Standard deviation, SE: Standard error
                                                                                                                                  Ayad et al.                                                                                                                                       
                                                                                                                                                                        Innovare Journal of Medical Science, Vol 4, Issue 3, 14-17
16
methods [1] for etilefrine hydrochloride and fenoterol hydrobromide 
or reported method [20] for pipazethate hydrochloride. The results 
showed that there is no significant difference between the proposed 
and official or reported methods. Results of different statistical data are 
shown in Table 4.
CONCLUSION
The simple and rapid procedure described in this paper can be an 
alternative to the more complex and expensive methods for assay of 
etilefrine hydrochloride, fenoterol hydrobromide, and pipazethate 
hydrochloride. The proposed method is easy and a very useful for the 
determination of the studied drug in pharmaceutical formulations and 
can be applied in laboratories for routine analysis.
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Table 4: Statistical data for the conductometric determination of 
naftidrofuryl etilefrine hydrochloride, fenoterol hydrobromide, 
and pipazethate hydrochloride using silver nitrate





Mean±SD 100.17±0.685 100.06±0.655 [1]
N 6 6
Variance 0.469 0.429
Student’s t-test 0.284 (2.228)*
F-test 1.093 (5.050)*
Fenoterol hydrobromide
Mean±SD 100.23±0.817 99.08±1.209 [1]
N 6 4
Variance 0.668 1.460
Student’s t-test 1.814 (2.306)*
F-test 2.186 (5.410)*
Pipazethate hydrochloride
Mean±SD 100.10±0.865 100.05±0.604 [29]
N 6 8
Variance 0.748 0.360
Student’s t-test 0.128 (2.179)*
F-test 2.078 (3.970)*
*Theoretical values of t and F at p=0.05. SD: Standard deviation
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